echemi logo
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Immunology News > Singapore approves use of Redsevefortreatment for PATIENTs with COVID-19

    Singapore approves use of Redsevefortreatment for PATIENTs with COVID-19

    • Last Update: 2020-06-17
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit

    , June 10, 2020 /PRNewswire/ -- Singapore has approved the use of the antiviral drug Ridshriver to treat new coronavirus infections, becoming the latest country to approve the use of Redseve, authorities said on June 10the U.Sauthorized emergency hospital use of Redsevein in early May, followed by Japan and South Korea, and Europe is considering following suitSingapore's health products regulator said the drug had been conditionally approved in Singapore to treat adult patients infected with the virus, such as those in need of enhanced respiratory supportimage source: "Given the urgent public health needs during the COVID-19 pandemic, it has accelerated the review of Redsweride," said the regulator, the Health Sciences Authorityas part of its approval, the FDA requires Gilead Sciences, inc., which developed the drug, to collect safety data and monitor its useSingapore initially controlled the virus through a rigorous detection and contact tracking system, only to prevent a future outbreak of severe outbreaks in low-paid foreign workers' dormitoriesthe city-state is currently the most infected country in Southeast Asia, with nearly 39,000 cases of infection, mostly foreign workersThe death toll is 25( approves anti-drug drug for COVID-19 patients
    This article is an English version of an article which is originally in the Chinese language on and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to with relevant evidence.